Journal article

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial: Clinical implications and limitations

MA Pohl, S Blumenthal, DJ Cordonnier, F De Alvaro, G DeFerrari, G Eisner, E Esmatjes, RE Gilbert, LG Hunsicker, JBL de Faria, R Mangili, J Moore, E Reisin, E Ritz, G Schernthaner, S Spitalewitz, H Tindall, RA Rodby, EJ Lewis

Journal of the American Society of Nephrology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2005

Abstract

Elevated arterial pressure is a major risk factor for progression to ESRD in diabetic nephropathy. However, the component of arterial pressure and level of BP control for optimal renal outcomes are disputed. Data from 1590 hypertensive patients with type 2 diabetes in the Irbesartan Diabetic Nephropathy Trial (IDNT), a randomized, double-blind, placebo-controlled trial performed in 209 clinics worldwide, were examined, and the effects of baseline and mean follow-up systolic BP (SBP) and diastolic BP and the interaction of assigned study medications (irbesartan, amlodipine, and placebo) on progressive renal failure and all-cause mortality were assessed. Other antihypertensive agents were adde..

View full abstract